Does G6PD deficiency cause further damage to red blood cells of patients with sickle cell anaemia? Article Swipe

MAKE IMPACT

Sofia Esperti , Camille Boisson , Mélanie Robert , Élie Nader , Agnès Cibiel , Céline Renoux , Françoise Horrand , Alexandra Gauthier , Solène Poutrel , Philippe Joly , Philippe Connes · YOU? · · 2022 · Open Access · · DOI: https://doi.org/10.1111/bjh.18417

Glucose-6-dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in the world,1 which leads to a lower level of reduced glutathione, an antioxidant, in red blood cells (RBCs). Most of the time, those who are affected have no symptoms. However, they should avoid specific triggers that may promote oxidative stress such as fava beans, that may fragilize RBCs and cause haemolysis. G6PD deficiency has been proposed to be a modulator of certain complications in sickle cell anaemia (SCA), such as stroke2 and vaso-occlusive crises,3 but others found no major role of G6PD deficiency in the clinical manifestations and haematological phenotype of SCA.4-6 The present study investigated the effects of G6PD deficiency on RBC deformability, RBC senescence markers, haematological parameters and clinical severity in SCA. We hypothesized that RBC oxidative stress would be greater in SCA patients with G6PD deficiency than those without, and this would be accompanied by greater alterations in RBC rheology. Seventy-one patients with homozygous sickle cell disease (SCA, HbSS), no recent blood transfusion or acute complication participated in the present study after giving written informed consent. Medical records were reviewed by two physicians to identify patients who had acute chest syndrome (ACS) or vaso-occlusive crises (VOC) in the four years preceding the study, as well as a diagnosis of osteonecrosis, glomerulopathy, retinopathy and leg ulcers. A patient was considered as having frequent VOC when the number of VOC per year was greater or equal to two. This study was performed in accordance with the Declaration of Helsinki and approved by the HCL Ethics committee (L14-127). Screening for G6PD deficiency in SCA patients was first done at the enzyme level in all patients. Both G6PD and pyruvate kinase (PK) activities were measured and the ratio G6PD/PK calculated. A ratio comprised between 0.5 and 1.5 indicates no deficiency. For hemizygotes or homozygotes, the ratio is very low (<0.10). When the ratio was lower than 0.5, high resolution melting (HRM) analysis was performed focusing on the Med and A(−) variants7 to detect a possible heterozygous carrier state. Haematological parameters were determined with a haematology analyser (Advia, Siemens, Rungis, France). Ektacytometry was carried out with the Laser-assisted optical rotational red cell analyser (Lorrca, RR-Mechatronics) with the oxygenscan module to measure RBC deformability (Elongation Index; EI) over an oxygen gradient and at 30 Pa, as previously described.8 Several parameters were derived: (1) EImax (normoxic RBC deformability), (2) EImin (the lowest RBC deformability reached during deoxygenation) and (3) PoS (the pO2 at which RBC deformability decreases below 95% of EImax during deoxygenation), which reflects the pO2 at which RBCs start to sickle during deoxygenation. Phosphatidylserine (PS) exposure at the outer membrane leaflet of RBCs and CD47 were assessed using Annexin V-PE (Miltenyi, 130-118-363) and anti-CD47-PE antibody (Miltenyi 130-101-348), respectively.9 Intracellular RBC reactive oxygen species (ROS) were determined using 2′,7′–dichlorofluorescin diacetate (DCFDA, Sigma-Aldrich, Saint-Quentin-Fallavier, France).9 DCFDA is a non-specific probe that allows the determination of the degree of overall oxidative stress in the cells by reacting with various reactive oxygen species. Despite the fact that nitric oxide may oxidize DCFDA, this probe seems sensitive enough to detect intracellular oxidative stress levels in RBCs in a pathophysiological context and for in vitro pharmacological modulation assessments.9 Ten patients had G6PD deficiency (six homozygotes, four hemizygotes), all A(−) variants. Age was not different between the two groups (23.7 ± 16.8 vs 24.9 ± 13.8 years in patients with and without G6PD deficiency, respectively). Biological results (Table 1) showed greater intracellular ROS content and higher percentage of positive RBCs for ROS in SCA patients with G6PD deficiency. RBC ROS level was also analysed in a group of healthy subjects (36.9 ± 7.8 years): positive RBCs = 55.0% ± 24.3%; median fluorescence intensity (MFI) = 0.57 ± 0.14. Both parameters were below the values found in the two SCA groups. The other markers were not different between the two groups. Table 2 shows no difference in the clinical parameters between the two groups. Bouguerra et al.10 previously showed higher numbers of PS-exposing RBCs and higher ROS level in the RBCs from non-SCA G6PD-deficient patients than from healthy volunteers. Indeed, it is not surprising that greater intracellular ROS levels were observed in SCA patients with G6PD deficiency than in those without in the present study. However, no difference was observed between the two groups for RBC senescence markers (percentage of RBCs exposing PS and CD47 expression), RBC deformability in both normoxia and hypoxia, the propensity of sickling (i.e., PoS), the level of anaemia (Hct and Hb) and haemolytic markers. Although some studies reported lower Hb concentrationds in SCA patients with G6PD deficiency compared to those without,11, 12 the majority of previous studies showed no difference in haematological parameters between the two populations.13, 14 Nevertheless, these results are quite surprising since oxidative stress is known to further reduce RBC deformability in SCA and fragilize RBC,9 as well as promote RBC senescence. The exact reasons for these discrepancies are not clearly understood. Although our study did not show further RBC alterations in G6PD-deficient patients, the higher baseline RBC oxidative stress found in this group justifies patients becoming acquainted with their G6PD genotype in order to avoid consuming oxidative substances that would further enhance oxidative stress and worsen their haematological phenotype. The clinical impact of G6PD deficiency in SCA is also debated in the literature. Some studies reported an association between cerebral vasculopathy and G6PD deficiency2, 15 while others did not find such an association.5, 6 Patients with a chronic transfusion programme were not included in this study and it was thus not possible to test whether G6PD deficiency was associated with brain infarcts or abnormal transcranial Doppler velocity since these patients usually have transfusion therapy. Instead, we tested the associations between G6PD deficiency and other acute and chronic complications. Although the sample size of our G6PD-deficient group was small, we did not detect any association which confirms previous studies.5, 13, 14 In conclusion, our study did not show any difference in the RBC rheological, haematological and clinical profiles between SCA patients with and without G6PD deficiency despite higher RBC oxidative stress in the former population. All authors listed have made a substantial, direct, and intellectual contribution to the work, and approved it for publication. The authors thank all the participants. This study was supported by the European Framework Horizon 2020 under grant agreement number 860436 (EVIDENCE). The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Data are available upon requests to the corresponding author.

Type

letter

Language

en

Landing Page

https://doi.org/10.1111/bjh.18417

PDF

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.18417

OA Status

bronze

Cited By

4

References

16

Related Works

10

OpenAlex ID

https://openalex.org/W4293870349

Raw OpenAlex JSON

OpenAlex ID

https://openalex.org/W4293870349

Canonical identifier for this work in OpenAlex

DOI

https://doi.org/10.1111/bjh.18417

Digital Object Identifier

Title

Does G6PD deficiency cause further damage to red blood cells of patients with sickle cell anaemia?

Work title

Type

letter

OpenAlex work type

Language

en

Primary language

Publication year

2022

Year of publication

Publication date

2022-08-16

Full publication date if available

Authors

Sofia Esperti, Camille Boisson, Mélanie Robert, Élie Nader, Agnès Cibiel, Céline Renoux, Françoise Horrand, Alexandra Gauthier, Solène Poutrel, Philippe Joly, Philippe Connes

List of authors in order

Landing page

https://doi.org/10.1111/bjh.18417

Publisher landing page

PDF URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.18417

Direct link to full text PDF

Open access

Yes

Whether a free full text is available

OA status

bronze

Open access status per OpenAlex

OA URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.18417

Direct OA link when available

Concepts

Medicine, Red Cell, Red blood cell, Hematology, Immunology, Pediatrics, Internal medicine

Top concepts (fields/topics) attached by OpenAlex

Cited by

4

Total citation count in OpenAlex

Citations by year (recent)

2024: 1, 2023: 3

Per-year citation counts (last 5 years)

References (count)

16

Number of works referenced by this work

Related works (count)

10

Other works algorithmically related by OpenAlex

Full payload